Australis Scientific

Australis Scientific operates at the intersection of medical devices, digital health, wearables, and neuromodulation, with a focused application in lower urinary tract symptoms such as overactive bladder and urinary incontinence. Its differentiation is primarily technological and clinical: the company is developing a compact, patch-based system that delivers peripheral nerve stimulation through a wearable form factor rather than relying solely on conventional clinical treatment pathways. The Confidanz Smart Patch gives Australis Scientific a specific product identity within the broader neuromodulation market, while its emphasis on human factors engineering and usability addresses a practical barrier in chronic-care devices. The company’s A$9.3 million corporate round led by Rohto Pharmaceutical and subsequent ANDHealth grant indicate support from both a strategic healthcare participant and an Australian digital-health ecosystem organization. Its current position is best characterized as an early-stage, clinically oriented medtech developer pursuing regulatory validation and commercialization rather than an established medical-device incumbent.

Australis Scientific’s trajectory shows progression from company formation and device development toward strategic financing and commercialization preparation. Founded in 2021, the company has focused on neuromodulation devices for lower urinary tract symptoms, including wearable systems based on transcutaneous tibial nerve stimulation. Nicky Agahari has served as Founder and CEO since June 2022, suggesting consistent founder-led management through the documented development period. The clearest financial inflection point occurred on Nov 24, 2025, when Rohto Pharmaceutical led a corporate round of approximately $6.0 million USD. A second financing event followed on May 25, 2026 through an ANDHealth-led grant, but its value is undisclosed. The company also received the MedTech Innovator 2025 Grand Prize, adding external validation during the transition from prototyping toward clinical and regulatory work. Its stated activities include clinical development, human factors engineering, device refinement, and commercialization efforts.